BMJ Open Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review

Anne R Cotter,¹ Kim Vuong,¹ Linda L Mustelin,² Yi Yang,¹ Malika Rakhmankulova,¹ Colleen J Barclay,³ Russell P Harris³

To cite: Cotter AR, Vuong K, Mustelin LL, *et al.* Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review. *BMJ Open* 2017;7:e017565. doi:10.1136/bmjopen-2017-017565

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2017-017565>).

Received 1 May 2017
Revised 29 August 2017
Accepted 25 September 2017

CrossMark

¹University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

²Department of Public Health, University of Helsinki, Helsinki, Finland

³Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, North Carolina, USA

Correspondence to

Colleen J Barclay;
cjbarcla@email.unc.edu

ABSTRACT

Objective A potential psychological harm of screening is unexpected diagnosis—labelling. We need to know the frequency and severity of this harm to make informed decisions about screening. We asked whether current evidence allows an estimate of any psychological harm of labelling. As case studies, we used two conditions for which screening is common: prostate cancer (PCa) and abdominal aortic aneurysm (AAA).

Design Systematic review with narrative synthesis.

Data sources and eligibility criteria We searched the English language literature in PubMed, PsychINFO and Cumulative Index of Nursing and Allied Health Literature (CINAHL) for research of any design published between 1 January 2002 and 23 January 2017 that provided valid data about the psychological state of people recently diagnosed with early stage PCa or AAA. Two authors independently used explicit criteria to review and critically appraise all studies for bias, applicability and the extent to which it provided evidence about the frequency and severity of harm from labelling.

Results 35 quantitative studies (30 of PCa and 5 of AAA) met our criteria, 17 (48.6%) of which showed possible or definite psychological harm from labelling. None of these studies, however, had either appropriate measures or relevant comparisons to estimate the frequency and severity of psychological harm. Four PCa and three AAA qualitative studies all showed clear evidence of at least moderate psychological harm from labelling. Seven population-based studies found increased suicide in patients recently diagnosed with PCa.

Conclusions Although qualitative and population-based studies show that at least moderate psychological harm due to screening for PCa and AAA does occur, the current quantitative evidence is insufficient to allow a more precise estimation of frequency and severity. More sensitive measures and improved research designs are needed to fully characterise this harm. In the meantime, clinicians and recommendation panels should be aware of the occurrence of this harm.

Strengths and limitations of this study

- Our systematic review included English language studies of all research designs and all psychological measures of people newly diagnosed with prostate cancer and abdominal aortic aneurysm.
- We examined both study quality (internal validity) and generalisability (external validity).
- We report both the design flaws of studies and their results.
- Although it is likely that most included studies included participants diagnosed by screening, some studies did not make this clear.
- Some studies reported results in a manner that made it impossible to determine the frequency and severity of harm from labelling.

INTRODUCTION

When a physician makes a diagnosis, a patient receives a label. Patients with unexplained symptoms may be reassured by such labelling, but asymptomatic patients given a label may experience negative psychological consequences as a result of an unexpected diagnosis. In this paper, we use the term ‘labelling’ to refer to a healthcare professional giving an unexpected diagnosis to an asymptomatic patient, usually in the process of screening.

In deciding about screening, any negative effects of labelling should be added to other harms and costs, and then weighed against any benefits. The negative effects of labelling would be most problematic if the label were unnecessary (ie, the patient was actually overdiagnosed), given prematurely (ie, earlier than would be needed to achieve the same benefit) or given to a patient not destined to benefit from earlier detection (ie, due to unavailability of effective treatment or due to limited life expectancy).

As these three categories often make up a majority of patients labelled by screening, it is important to quantify this harm as much as possible.

An older study of labelling found people diagnosed with hypertension had substantially increased absenteeism from work in the year after compared with the year prior to labelling (80% increase compared with 9% increase among workers not labelled). In another older study, 41% of asymptomatic adolescents previously screened and told they had a 'heart problem' had some restriction placed on their activity, although 79% had no actual cardiac disease.¹⁻³ Yet, guideline panels rarely discuss the potential harm of labelling in making recommendations for screening. For example, of the 19 screening recommendations made by the US Preventive Services Task Force between January 2015 and January 2017, for only one has considerations of labelling been a factor (unpublished data, RPH, April 2017). We asked what current evidence is available, and what available evidence tells us about the frequency and severity of negative psychological effects from labelling of two conditions, prostate cancer (PCa) and abdominal aortic aneurysm (AAA), that are the focus of widespread screening.

METHODS/LITERATURE SEARCH

We conducted a systematic review of research studies of any design published in the English language between 1 January 2002 and 23 January 2017 that assessed the psychological state of patients newly diagnosed with PCa or AAA. We chose this time period to focus on the most recent literature that would involve the current public psychological response to labelling, and that would most likely be included in new systematic reviews of screening. We chose these conditions, one cancer and one non-cancer, as they are commonly diagnosed by screening, but not all are immediately treated after diagnosis. This time lag means that psychological harms of diagnosis can be observed without interference from additional psychological effects of treatment. We also focused only on studies with newly diagnosed *early* stage PCa and AAA. Although included studies did not always discuss whether participants were diagnosed by screening or by symptoms, the natural history of PCa and AAA is such that early stage patients are almost always asymptomatic, and thus most likely to have been diagnosed by screening.

Study inclusion or exclusion

After formulating our research question in the population, intervention/exposure, comparison, timing, and outcome (PICOTS) format (table 1), we worked with a research librarian to search PubMed, PsychINFO and Cumulative Index of Nursing and Allied Health Literature (CINAHL) for articles on PCa and AAA published between 1 January 2002 and 23 January 2017 (search terms, online supplementary appendix A). We also

searched the reference lists of included studies for further studies meeting our criteria.

Two trained reviewers (the authors) independently examined each abstract identified by our searches, and the full text of any article that any single reviewer thought could meet inclusion criteria. For each full-text study, one reviewer extracted data, a second reviewer checked the extraction and then the first reviewer compiled extraction notes and comments. Uncertainty or disagreements between abstract or full-text reviewers about inclusion were resolved by discussion and final decisions were made by a third senior reviewer. Data extracted included the recruitment site, sample size, average age of the study population, comparison group (when available), measurement instruments used to assess psychological state, assessment time points and results.

Definitions

We categorised all included studies into one of three research designs: quantitative, qualitative and population-based studies. Quantitative studies were those using quantitative rating scales in defined populations. Qualitative studies were those that did not use rating scales but rather engaged participants in structured or semi-structured interviews and thus reported themes rather than frequencies. Population-based studies were studies from large databases providing frequencies of fatal or severe complications (eg, suicide rates) associated with a diagnosis of either PCa or AAA. As most cases of PCa and AAA are detected by screening at an early stage, we accepted population-based studies that did not stratify results by stage at diagnosis. For these studies, we also collected information about outcomes such as cardiovascular disease and psychiatric medical care that could have been associated with psychological distress, as well as longer-term outcomes that could be related to psychological distress. Our focus, however, was on outcomes that occurred shortly after diagnosis.

Determination of quality and answering the question of harm from labelling

We assessed the 'quality' (ie, internal validity) and generalisability (ie, applicability or external validity) of each of the three types of studies in two steps, using criteria modified from the US Preventive Services Task Force Procedure Manual (uspreventiveservicestaskforce.org) (table 2), described below.

Quantitative studies

After all articles meeting eligibility criteria were selected, we assessed each included quantitative study first for quality and second for the degree to which it answered our research question. Quality assessment addressed validity, reliability and response rate of the psychological measure (ie, greater than 60%) and measurement bias (ie, equal measurement of compared groups with valid and reliable measures).

Table 1 Study eligibility criteria (studies meeting these criteria are included)

	Inclusion criteria	Exclusion criteria
Population	Studies enrolling asymptomatic patients diagnosed with localised PCa or AAA through screening.	Studies of men diagnosed with advanced PCa or AAA >5.5 cm.
Exposure	Recent PCa or AAA diagnosis; we included studies of asymptomatic patients diagnosed with PCa or AAA either before deciding on treatment or who recently decided to receive active surveillance or watchful waiting. All participants must have completed a psychological assessment soon after diagnosis.	Studies assessing patients already undergoing treatment or where current treatment could not be determined. Studies that assessed the psychological effects of patients with false positive or indeterminate screening results, studies of 'pre-disease states' and genetic screening.
Comparison	Unlabelled similar control group preferred but not required; control assessment of participants before labelling preferred but not required. Consideration of relevant control group was done after eligibility was assessed.	
Outcome	Any validated measure of psychological status, suicide and psychiatric problems.	Non-psychological outcomes, such as screening behaviour, satisfaction with care, risk perception, changes in decision making or knowledge. Studies that only assess sexual function, incontinence, relationships, intimacy outcomes or effects in family members. Studies without the desired causal direction, such as psychological state as a predictor of disease exacerbation.
Time frame	Studies that assessed psychological status within 3 months of diagnosis or within a mean of 6 months. Studies in which psychological state was assessed by the patient in retrospect (eg, by asking patients at a later time how they were doing soon after diagnosis). Studies where time since diagnosis was unclear, if wording such as 'recent diagnosis' was used or if patients were assessed before their first clinic appointment.	
Study design	Original, empirical research in any study design.	Commentaries, editorials and reviews.
Setting	Research conducted in the USA or countries with populations and services similar to the USA (ie, OECD countries).	Research conducted in a non-OECD country.
Language	Studies published in English.	Publications not available in English.

AAA, abdominal aortic aneurysm; OECD, Organization for Economic Cooperation and Development; PCa, prostate cancer.

Table 2 Criteria for assessing quality and extent to which article answered the questions of interest

Study type	Criteria assessed
Quantitative	Quality criteria <ul style="list-style-type: none"> ▶ Response rate for psychological measures was above 60% ▶ Analysis included all cases unless justified explanation for exclusion ▶ Outcomes of interest assessed with validated measures ▶ Measurements done in the same way for all participants Extent to which study answered our research question <ul style="list-style-type: none"> ▶ Applicability of the study participants to a general primary care population in the USA ▶ Study includes one of following relevant comparison groups to assess change from prescreening: (1) prediagnosis in same individuals; (2) screen negative group; (3) population norms and (4) similar unscreened group ▶ Addressed potential confounders ▶ The results presented as frequencies of specific psychological states rather than only group means
Qualitative	<ul style="list-style-type: none"> ▶ Applicability of participants to a general primary care population in the USA ▶ Consistent interviewing methods for all participants ▶ Systematic and rational approach to identification and coding of themes
Population-based studies	<ul style="list-style-type: none"> ▶ Population applicable to a general primary care population in the USA ▶ Valid measures applied consistently for all participants ▶ Valid measures of suicide/psychiatric problem outcomes ▶ Comparison with people not recently diagnosed with either PCa or AAA

AAA, abdominal aortic aneurysm; PCa, prostate cancer.

As our research question was to determine the change in the frequency and severity of specific psychological states as a result of screening in the general primary care population, we also assessed each study for its ability to answer the research question. Thus, we examined the presence of a relevant comparison group, the applicability of study participants to a primary care population (which is the usual population for screening) and for the presentation of results in frequencies of specific psychological states. As important psychological harm from screening may not reach pathological levels, we assessed whether studies used only general psychological measures (which are often insensitive to less severe distress) or whether they

also used more sensitive condition-specific measures. As above, these assessments were done independently by two co-authors, with discrepancies resolved by discussion and, when necessary, appeal to a third senior author. [Table 2](#) provides a list of the assessment criteria.

After the assessments above, we grouped quantitative studies into one of four mutually exclusive categories ([table 3](#)), depending on the presence of a relevant comparison group, presentation of results and the results of the psychological measures. These categories are: no evidence of harm, possible evidence of harm, definite evidence of harm and uncertain evidence of harm ([table 3](#)).

Table 3 Assessments of quantitative studies

Assessment	Comparison group present*	Specification of results†	Number
No evidence of harm	Yes	Gives frequency and severity of psychological state; no statistical difference with comparison group	AAA: 0 PCa: 4 ^{23–25 52} Total: 4
Possible evidence of harm	None	Can give mean or frequency and severity; psychological measure shows clear problems	AAA: 1 ²² PCa: 9 ^{39–44 47–49} Total: 10
Definite evidence of harm	Yes	Can give mean or frequency and severity; statistically significantly worse than comparison group	AAA: 1 ²¹ PCa: 6 ^{26 36 37 45 46 50} Total: 7
Uncertain evidence of harm	None	The results only give mean with uncertainty whether psychological measure shows clear problems	AAA: 3 ^{18–20} PCa: 11 ^{34–38 38–42 51} Total: 14

*May be prediagnosis, prescreening, screen negative, population norm and unscreened group.

†May or may not use condition-specific measure of psychological state; may or may not use representative population.

AAA, abdominal aortic aneurysm; PCa, prostate cancer.

Qualitative studies and population-based studies

We assessed the quality of qualitative studies and population-based studies using criteria in [table 2](#). We then extracted themes from the qualitative studies, reflecting different types of psychological problems without ranking their severity. Frequency of problems cannot be obtained from this type of study. A limited number of outcomes were reported in the population-based studies, all of which were rare but severe (eg, suicide, cardiovascular events and psychiatric hospitalisation).

Patient involvement

Patients were not involved in this systematic review. As we did not study patients but rather medical studies, we did not seek ethics committee approval.

Protocol and registration

There was no written protocol or registration of this systematic review.

Publication bias

We did not examine publication bias.

RESULTS

Study selection

A total of 5348 articles were identified through database searching. Of these, 403 were duplicates and removed, leaving 4945 unique articles (308 AAA, 4637 PCa). At title and abstract review, a total of 4581 were excluded; 364 articles were assessed at full-text review (55 AAA, 309 PCa). For those articles that were excluded at full-text review, the most frequent reasons for exclusion were the wrong patient population (eg, already treated; 135/315, 42.9%) and the wrong time frame (eg, psychological assessment longer than 6 months after diagnosis, 59/315, 18.7%). A total of 49 studies (8 AAA, 41 PC) met inclusion criteria. Seven were qualitative studies (three AAA; four PCa)⁴⁻¹⁰; seven were population-based studies (all were PCa)¹¹⁻¹⁷ and 35 were quantitative studies (5 AAA; 30 PCa).¹⁸⁻⁵² No studies were excluded for bias (see Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) figure, online supplementary appendix B).

Quantitative studies

Of the 35 included quantitative studies, 13 (37.1%)^{21 23-28 36 37 45 46 50 52} included relevant comparison groups, only 2 (5.7%)^{44 47} used more sensitive condition-specific measures and only 5 (14.3%)^{18 21 36 46 52} involved generally representative populations. Nearly half (17/35, 48.6%) of the studies indicated the presence of possible or definite psychological harm from the recent diagnosis; seven of these 17 studies (41.2%)^{21 26 36 37 45 46 50} included a relevant comparison group, although only one⁴⁶ of these seven studies presented results in terms of frequencies and severity. This study, however, used only general, less sensitive measures in a non-representative population. For more than a third (14/35,

40.0%)^{18-20 27-35 38 51} of the included studies, the results were presented in such a way that the evidence of any harm was uncertain (ie, no comparison group and the results were given only in means, making determination of frequency and severity impossible). Only four studies (11.4%)^{23-25 52} used relevant comparison groups such that we could conclude that there was no evidence of harm, although all four of these studies used less sensitive general measures and three studied non-representative populations ([table 3](#) and online supplementary appendix C).

No study presented results in terms of frequencies and used condition-specific measures with a relevant comparison group in a representative population, criteria for allowing a valid estimate of the frequency and severity of psychological harm from labelling. By inspection, there were no major differences in the results between AAA and PCa studies, although there were so few AAA studies that no statistical comparison could be made.

Because of clinical heterogeneity—multiple different measurement instruments and multiple different psychological outcomes—in these studies, no meta-analysis was possible.

Qualitative studies

Our systematic review identified three AAA and four PCa qualitative studies addressing the psychological effect of labelling. Nine themes of psychological effects emerged from the AAA qualitative studies and 10 from the PCa studies. Themes common to both conditions included shock, anxiety, fatalism, general distress and burden about protecting others from worrying. Several other themes were reported from one or the other condition alone ([table 4](#) and online supplementary appendix D).

Table 4 Qualitative study themes—note that the number of themes does not add to number of studies because some studies had multiple themes

Theme	AAA studies	PCa studies
Shock	2 ^{4 5}	3 ⁶⁻⁸
Anxiety	2 ^{5 9}	2 ^{6 10}
Fatalism	3 ^{4 5 9}	3 ^{6 8 10}
Distress	1 ⁵	1 ¹⁰
Burden about protecting others from worrying (especially family members)	2 ^{5 9}	1 ⁶
Guilt/regret	2 ^{5 9}	—
Helplessness/powerlessness	1 ⁵	—
Uncertainty	2 ^{4 5}	—
Depression	—	1 ¹⁰
Denial	—	1 ¹⁰
Loneliness	—	3 ^{6 8 10}
Psychological impact of sexual dysfunction	—	1 ⁶

AAA, abdominal aortic aneurysm; PCa, prostate cancer.

Table 5 Population-based studies of prostate cancer diagnosis

	Outcome	Studies (n)
Suicide	Peaked in first week	1 ¹¹
	Peaked in first 3 months	2 ^{12 13}
	Especially among single, separated or divorced or widowed ¹²	
	Compared with other solid cancers ¹³	
	Peaked WITHIN first 6 months	4 ^{11–14}
	Especially among single, separated or divorced or widowed ¹²	
	Compared with other solid cancers ¹³	
	Higher than population norms in first year	4 ^{11–13 15}
	Increased over population norms ¹¹	
	Especially among single, separated or divorced or widowed ¹²	
	Compared with other solid cancers ¹³	
	Pooled data ¹⁵	
	Higher in second year	2 ^{11 15}
	Increased over population norms ¹¹	
	Pooled data ¹⁵	
Cardiovascular outcomes	Higher over lifetime	2 ^{16 17}
	Among ever users of prescription for mental health than never users ¹⁶	
Cardiovascular outcomes	No increased risk: among watchful waiting and localised T1c tumours ¹⁵	1 ¹⁵
	Peaked in first week compared with later weeks	1 ¹¹
Psychiatric outcomes	Peaked in first month	1 ¹²
	Increased hospitalisations due to depression	1 ¹⁸
	Higher antidepressant use	1 ¹⁸

All seven qualitative studies showed evidence of negative psychological effects of labelling, which we assessed as at least moderate in severity in that they interfered with individuals' usual lives.

These studies primarily involved volunteers from non-representative groups; thus they cannot be used to estimate the population frequency of psychological symptoms due to labelling. They do, however, provide more in-depth information about the severity of some patients' reactions to diagnosis. None of these studies assessed patients for pathological levels of psychological states (frequently the target of quantitative measures), but they do demonstrate considerable distress.

Population-based studies

Our systematic review yielded seven PCa population-based studies from two different countries, the USA and Sweden. Only three outcomes were studied: suicide, cardiovascular outcomes and psychiatric outcomes. All seven studies found increased suicide rates or medical care for psychological problems compared with similar groups without PCa, usually early after diagnosis (table 5 and online supplementary appendix E). Although these outcomes are quite severe, they were also infrequent, yet higher than relevant comparison groups. It is likely that many of these newly diagnosed patients had PCa detected by screening.

DISCUSSION

Our systematic review examined negative psychological states of individuals soon after receiving a label of either PCa or AAA and whether these states could be attributed to unexpected diagnosis—labelling—usually by screening. We found that nearly half (48.6%) of the 35 quantitative studies and all of the qualitative (n=7) and population-based studies (n=7) showed either possible or definite evidence of psychological harm due to labelling. Only 11.4% (4/35) of the quantitative studies found no evidence of harm, and none of these studies used more sensitive condition-specific measures and only one studied a representative population (table 3 and online supplementary appendix C). The qualitative and population-based studies show that this harm can be at least moderate in severity, although they do not allow us to estimate the frequency of life-changing distress. Population-based studies in particular show increased suicide rates in men recently diagnosed with PCa.

We also found that the literature concerning labelling has a number of deficiencies. A previous review from our group⁵³ found a lack of studies on labelling. This study extends that finding to examine the quality and results of studies that have been done. In this review, we found that few studies used appropriate measures and studied appropriate populations. Most studies had no relevant

comparison group to determine whether a negative psychological state after diagnosis was pre-existing or was truly caused by labelling. Most studies gave results in ways that prevented calculation of the frequency of people harmed in important ways.

Our findings are in agreement with our knowledge of previous studies of long-term negative psychological effects associated with labelling.^{1-3 54 55} As noted earlier, there were two pioneer studies that gave early evidence of the harms of labelling. Subsequent studies have confirmed that labelling may have adverse effects on psychological well-being and perceived health.²⁵⁴⁻⁵⁷ Our review of more recent studies found that although a number of studies have examined the psychological state of individuals recently labelled, no study defined the construct of labelling. Indeed, no study in our review even used the term 'labelling'.

This study has several limitations. We only reviewed two of many possible risk factors and diseases that are currently the target of screening programme. It is likely that the labelling effect differs by the label. We also looked primarily at the time shortly after a diagnosis, with the exception of the population-based studies which followed individuals over a longer period of time. Thus, the time course of any negative psychological effects is uncertain. Longitudinal studies would be needed to examine this issue, although these studies would have the challenge of separating negative effects of labelling from the psychological effects of treatment. In some of our included studies, it was difficult to determine the exact timing between diagnosis and psychological assessment. It was also unclear whether participants had decided on a treatment method at that time. Anticipated treatment could influence a patient's psychological state. We examined only studies in the English language; a review of non-English language studies is needed.

Another limitation is that some studies reported results in such a way that the frequency and severity of any psychological problems could not be determined. In future, it would be helpful for quantitative studies to report both the frequency and the severity of various psychological states. In addition, the great majority of quantitative studies used only general psychological measures, while condition-specific measures are likely more sensitive to the psychological distress usually experienced by individuals who have been labelled.²³ Thus, the quantitative studies we included may have systematically underestimated the frequency and severity of negative psychological states. Even low-grade distress, if experienced by a large number of people, should be considered a substantial concern for a screened population.

Although not all included studies were clear that all of their participants were diagnosed by screening, by including in our review only quantitative and qualitative studies that provided results for *early* stage PCa and AAA, conditions that are almost always asymptomatic in their early stage, we ensured that these results are primarily if not entirely for patients diagnosed by screening. For

population-based studies that often do not stratify results by stage at diagnosis, we focused on outcomes shortly after diagnosis. In any case, the inclusion of even a small number of symptomatic patients would likely have biased the results in the direction of less psychological harm. Thus, it is possible that our review underestimates the psychological effects of labelling due to diagnosis by screening.

Although we included qualitative studies, we are aware that, in general, they do not provide adequate evidence about the frequency of negative psychological states. They can, however, provide a deeper understanding of the severity of psychological distress associated with labelling.

Finally, few papers contained a relevant comparison group and those that did often used less than optimal comparisons. It is interesting to consider what an ideal comparison group would be. Because the very idea of screening may have negative psychological effects for some, the ideal comparison group would be a similar group in the general population who had not even been offered screening.^{58 59} Because the severity of negative psychological effects of labelling likely differs by one's usual psychological state, it is important to make sure that the psychological state of individuals in the comparison group matches that of the labelled group before diagnosis.

Lack of appropriate comparison groups and pre-diagnostic psychological measurements in studies makes it difficult to interpret reported levels of psychological distress and makes us, for some studies (ie, those assessed as 'uncertain evidence of harm'), uncertain about the extent to which we can attribute post-labelling psychological distress found to labelling itself. Also, some studies excluded individuals who had a history of mental illness and this may reduce generalisability of the results to real populations and may thus underestimate the effect of labelling on a particularly vulnerable population.

The main strengths of this systematic review are that we were able to look at different types of studies—quantitative, qualitative and population-based studies. Each helped to give a different understanding of the possible influence of labelling on psychological state. Furthermore, we were able to identify specific instruments that were used in each of these studies, such as the short form 36 item health survey (SF-36), and compare and contrast these general measures with ones that were more condition specific. The general measures found less psychological distress than the condition-specific measures.

Our findings suggest that when screening guidelines are being created, the harms of labelling should be considered when weighing benefits and harms. Even if the evidence is scant, guideline developers should consider the potential psychological harm of labelling. In addition, practitioners should be aware of the potential for labelling so that they can inform patients when making screening decisions and offer support if a patient is labelled.

Our findings should also send a message to researchers. Even with the limitations above, we found adequate evidence that labelling is a potential harm of screening. It is clear that the construct has yet to be fully and precisely defined, and that a valid and reliable measure of the psychological harm of labelling has yet to be developed. Only with more and better definition of labelling and better measures will we be able to accurately estimate the frequency, magnitude and time pattern of labelling harms. We need to know much more about variation of labelling effects across different conditions and among different types of individuals.

CONCLUSIONS

We conclude that labelling is a potential psychological harm of screening. It is a real phenomenon that has been underappreciated and understudied. We need more and better research on labelling to be able to weigh all of the potential benefits and potential harms of screening programme. In the meantime, clinicians and guideline developers should be aware of the potential harm of labelling when assisting patients in deciding about screening.

Contributors Conceptual design and organisation; assess complex articles and resolving disagreements: RPH. Organisation of initial search and initial database: CJB. Maintenance of database: ARC and KV. Updating searches: YY and MR. Initial assessment of abstracts, full-text articles: KV, ARC, LLM, YY and MR. Completing evidence tables and revision of manuscript: all authors. Initial draft of manuscript: LLM. All authors approved of the final manuscript.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No further data available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Haynes RB, Sackett DL, Taylor DW, *et al.* Increased absenteeism from work after detection and labeling of hypertensive patients. *N Engl J Med* 1978;299:741–4.
- Bloom JR, Monterossa S. Hypertension labeling and sense of well-being. *Am J Public Health* 1981;71:1228–32.
- Bergman AB, Stamm SJ. The morbidity of cardiac nondisease in schoolchildren. *N Engl J Med* 1967;276:1008–13.
- Gunasekera RC, Moss J, Crank H, *et al.* Patient recruitment and experiences in a randomised trial of supervised exercise training for individuals with abdominal aortic aneurysm. *J Vasc Nurs* 2014;32:4–9.
- Pettersson M, Bergbom I. To be under control: a qualitative study of patients' experiences living with the diagnosis of abdominal aortic aneurysm. *J Cardiovasc Nurs* 2013;28:387–95.
- Ervik B, Nordøy T, Asplund K. Hit by waves—living with local advanced or localized prostate cancer treated with endocrine therapy or under active surveillance. *Cancer Nurs* 2010;33:382–9.
- Wall DP, Kristjanson LJ, Fisher C, *et al.* Responding to a diagnosis of localized prostate cancer: men's experiences of normal distress during the first 3 postdiagnostic months. *Cancer Nurs* 2013;36:E44–50.
- Wallace M, Storms S. The needs of men with prostate cancer: results of a focus group study. *Appl Nurs Res* 2007;20:181–7.
- Hansson A, Brodersen J, Reventlow S, *et al.* Opening Pandora's box: The experiences of having an asymptomatic aortic aneurysm under surveillance. *Health Risk Soc* 2012;14:341–59.
- Kronenwetter C, Weidner G, Pettengill E, *et al.* A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial. *Cancer Nurs* 2005;28:99–107.
- Fall K, Fang F, Mucci LA, *et al.* Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. *PLoS Med* 2009;6:e1000197.
- Fang F, Keating NL, Mucci LA, *et al.* Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. *J Natl Cancer Inst* 2010;102.
- Dalela D, Krishna N, Okwara J, *et al.* Suicide and accidental deaths among patients with non-metastatic prostate cancer. *BJU Int* 2016;118:286–97.
- Carlsson S, Sandin F, Fall K, *et al.* Risk of suicide in men with low-risk prostate cancer. *Eur J Cancer* 2013;49:1588–99.
- Bill-Axelsson A, Garmo H, Lambe M, *et al.* Suicide risk in men with prostate-specific antigen-detected early prostate cancer: a nationwide population-based cohort study from PCBaSe Sweden. *Eur Urol* 2010;57:390–5.
- Klaassen Z, Jen RP, DiBianco JM, *et al.* Factors associated with suicide in patients with genitourinary malignancies. *Cancer* 2015;121:1864–72.
- Bill-Axelsson A, Garmo H, Nyberg U, *et al.* Psychiatric treatment in men with prostate cancer—results from a Nation-wide, population-based cohort study from PCBaSe Sweden. *Eur J Cancer* 2011;47:2195–201.
- Lederle FA, Johnson GR, Wilson SE, *et al.* Quality of life, impotence, and activity level in a randomized trial of immediate repair versus surveillance of small abdominal aortic aneurysm. *J Vasc Surg* 2003;38:745–52.
- De Rango P, Verzini F, Parlani G, *et al.* Quality of life in patients with small abdominal aortic aneurysm: the effect of early endovascular repair versus surveillance in the CAESAR trial. *Eur J Vasc Endovasc Surg* 2011;41:324–31.
- Knops AM, Goossens A, Ubbink DT, *et al.* A decision aid regarding treatment options for patients with an asymptomatic abdominal aortic aneurysm: a randomised clinical trial. *Eur J Vasc Endovasc Surg* 2014;48:276–83.
- Ashton HA, Buxton MJ, Day NE, *et al.* The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. *Lancet* 2002;360:1531–9. https://auth.lib.unc.edu/ezproxy_auth.php?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=2003151432&site=ehost-live&scope=site
- Eisenstein EL, Davidson-Ray L, Edwards R, *et al.* Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms. *J Vasc Surg* 2013;58:302–10.
- Selli C, Bjartell A, Burgos J, *et al.* Burden of illness in prostate cancer patients with a low-to-moderate risk of progression: A one-year, pan-european observational study. *Prostate Cancer* 2014;2014:472949.
- Torvinen S, Färkkilä N, Sintonen H, *et al.* Health-related quality of life in prostate cancer. *Acta Oncol* 2013;52:1094–101.
- Vasaraïnen H, Lokman U, Ruutu M, *et al.* Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. *BJU Int* 2012;109:1614–9.
- Ishihara M, Suzuki H, Akakura K, *et al.* Baseline health-related quality of life in the management of prostate cancer. *Int J Urol* 2006;13:920–5.
- Oba A, Nakaya N, Hasumi M, *et al.* Psychosocial longitudinal study profile and distress of couples in relation to the conduct of prostate biopsy. *Jpn J Clin Oncol* 2014;44:463–71.
- Acar C, Schoffeleer CC, Tillier C, *et al.* Quality of life in patients with low-risk prostate cancer. A comparative retrospective study: brachytherapy versus robot-assisted laparoscopic prostatectomy versus active surveillance. *J Endourol* 2014;28:117–24.
- Berry DL, Ellis WJ, Russell KJ, *et al.* Factors that predict treatment choice and satisfaction with the decision in men with localized prostate cancer. *Clin Genitourin Cancer* 2006;5:219–26.
- Chhatre S, Wein AJ, Malkowicz SB, *et al.* Racial differences in well-being and cancer concerns in prostate cancer patients. *J Cancer Surviv* 2011;5:182–90.
- Couper JW, Love AW, Dunai JV, *et al.* The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. *Med J Aust* 2009;190:S86–9.
- Jayadevappa R, Malkowicz SB, Wittink M, *et al.* Comparison of distribution- and anchor-based approaches to infer changes in

- health-related quality of life of prostate cancer survivors. *Health Serv Res* 2012;47:1902–25.
33. Jayadevappa R, Johnson JC, Chhatre S, *et al.* Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. *Cancer* 2007;109:2229–38.
 34. Loiselle CG, Edgar L, Batist G, *et al.* The impact of a multimedia informational intervention on psychosocial adjustment among individuals with newly diagnosed breast or prostate cancer: a feasibility study. *Patient Educ Couns* 2010;80:48–55.
 35. Siston AK, Knight SJ, Slimack NP, *et al.* Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study. *Urology* 2003;61:172–8.
 36. Korfage IJ, de Koning HJ, Roobol M, *et al.* Prostate cancer diagnosis: the impact on patients' mental health. *Eur J Cancer* 2006;42:165–70.
 37. Perczek RE, Burke MA, Carver CS, *et al.* Facing a prostate cancer diagnosis: who is at risk for increased distress? *Cancer* 2002;94:2923–9.
 38. Mohan R, Beydoun H, Barnes-Ely ML, *et al.* Patients' survival expectations before localized prostate cancer treatment by treatment status. *J Am Board Fam Med* 2009;22:247–56.
 39. Bisson JI, Chubb HL, Bennett S, *et al.* The prevalence and predictors of psychological distress in patients with early localized prostate cancer. *BJU Int* 2002;90:56–61.
 40. Chambers SK, Zajdlewicz L, Youlden DR, *et al.* The validity of the distress thermometer in prostate cancer populations. *Psychooncology* 2014;23:195–203.
 41. Mohamed NE, Bovbjerg DH, Montgomery GH, *et al.* Pretreatment depressive symptoms and treatment modality predict post-treatment disease-specific quality of life among patients with localized prostate cancer. *Urol Oncol* 2012;30:804–12.
 42. Punnen S, Cowan JE, Dunn LB, *et al.* A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. *BJU Int* 2013;112:E67–E75.
 43. Soloway CT, Soloway MS, Kim SS, *et al.* Sexual, psychological and dyadic qualities of the prostate cancer 'couple'. *BJU Int* 2005;95:780–5.
 44. van den Bergh RC, Essink-Bot ML, Roobol MJ, *et al.* Anxiety and distress during active surveillance for early prostate cancer. *Cancer* 2009;115:3868–78.
 45. Love AW, Scealy M, Bloch S, *et al.* Psychosocial adjustment in newly diagnosed prostate cancer. *Aust N Z J Psychiatry* 2008;42:423–9.
 46. Wade J, Rosario DJ, Macefield RC, *et al.* Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. *J Clin Oncol* 2013;31:4235–41.
 47. Bellardita L, Rancati T, Alvisi MF, *et al.* Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *Eur Urol* 2013;64:30–6.
 48. Bill-Axelsson A, Garmo H, Holmberg L, *et al.* Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. *Eur Urol* 2013;64:920–8.
 49. Steginga SK, Occhipinti S, Gardiner RA, *et al.* Prospective study of men's psychological and decision-related adjustment after treatment for localized prostate cancer. *Urology* 2004;63:751–6.
 50. Alexander KE, Chambers S, Spurdle AB, *et al.* Association between single-nucleotide polymorphisms in growth factor genes and quality of life in men with prostate cancer and the general population. *Qual Life Res* 2015;24:2183–93.
 51. Parker PA, Davis JW, Latini DM, *et al.* Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. *BJU Int* 2016;117:469–77.
 52. Kent EE, Malinoff R, Rozjabek HM, *et al.* Revisiting the surveillance epidemiology and end results cancer registry and medicare health outcomes survey (seer-mhos) linked data resource for patient-reported outcomes research in older adults with cancer. *J Am Geriatr Soc* 2016;64:186–92.
 53. DeFrank JT, Barclay C, Sheridan S, *et al.* The psychological harms of screening: the evidence we have versus the evidence we need. *J Gen Intern Med* 2015;30:242–8.
 54. Hamer M, Batty GD, Stamatakis E, *et al.* Hypertension awareness and psychological distress. *Hypertension* 2010;56:547–50.
 55. Jørgensen P, Langhammer A, Krokstad S, *et al.* Diagnostic labelling influences self-rated health. A prospective cohort study: the HUNT Study, Norway. *Fam Pract* 2015;32:492–9.
 56. Barger SD, Muldoon MF. Hypertension labelling was associated with poorer self-rated health in the Third US National Health and Nutrition Examination Survey. *J Hum Hypertens* 2006;20:117–23.
 57. Whaley-Connell A, Shlipak MG, Inker LA, *et al.* Awareness of kidney disease and relationship to end-stage renal disease and mortality. *Am J Med* 2012;125:661–9.
 58. Brodersen J, Thorsen H, McKenna S, *et al.* Assessing psychosocial/quality of life outcomes in screening: how do we do it better? *J Epidemiol Community Health* 2005;59:609.
 59. Marteau TM, Kim LG, Upton J, *et al.* Poorer self assessed health in a prospective study of men with screen detected abdominal aortic aneurysm: a predictor or a consequence of screening outcome? *J Epidemiol Community Health* 2004;58:1042–6.

Correction: Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review

Cotter AR, Vuong K, Mustelin LL, *et al.* Do psychological harms result from being labelled with an unexpected diagnosis of abdominal aortic aneurysm or prostate cancer through screening? A systematic review. *BMJ Open* 2017;7:e017565. doi:10.1136/bmjopen-2017-017565

The first five authors share first authorship: Anne R Cotter, Kim Vuong, Linda L Mustelin, Yi Yang and Malika Rakhmankulova.

Author 'Linda L Mustelin' should be written without a middle initial as 'Linda Mustelin'. She is also has the following additional affiliation:

University of North Carolina, School of Public Health, Chapel Hill, North Carolina, USA

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

BMJ Open 2018;8:e017565corr1. doi:10.1136/bmjopen-2017-017565corr1